William A. Gray

William A. Gray

Auto-generated profile, based on publicly available information

William A. Gray

Lankenau Heart Institute/Main Line Health, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in The Lancet
Verified
Journal Article
Closed access
WGWilliam A Gray
William A Gray
KKKoen Keirse
Koen Keirse
YSYoshimitsu Soga
Yoshimitsu Soga
ABAndrew Benko
Andrew Benko
ABAnvar Babaev
Anvar Babaev
TZThomas Zeller
Thomas Zeller

1 June 2021 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
GTGunnar Tepe
Gunnar Tepe
MBMarianne Brodmann
Marianne Brodmann
MWMartin Werner
Martin Werner
WBWilliam Bachinsky
William Bachinsky
AHAndrew Holden
Andrew Holden
WGWilliam A. Gray
William A. Gray
The study sought to compare short-term outcomes in patients with femoropopliteal artery calcification receiving vessel preparation with intravascular lithotripsy (IVL) or percutaneous transluminal angioplasty (PTA) prior to drug-coated balloon (DCB) for symptomatic peripheral artery disease. Endovascular treatment of calcified peripheral artery lesions is associated with suboptimal vessel expansion and increased complication risk. Although initial results from single-arm studies with IVL have been reported, comparative evidence from randomized trials is lacking for most devices in the presence of heavy calcification. The Disrupt PAD III (Shockwave Medical Peripheral Lithoplasty System Study for PAD) randomized trial enrolled patients with moderate or severe calcification in a femoropopliteal artery who underwent vessel preparation with IVL or PTA prior to DCB or stenting. The primary endpoint was core lab-adjudicated procedural success (residual stenosis ≤30% without flow-limiting dissection) prior to DCB or stenting. In patients receiving IVL (n = 153) or PTA (n = 153), procedural success was greater in the IVL group (65.8% vs. 50.4%; p = 0.01) and the percentage of lesions with residual stenosis ≤30% (66.4% vs. 51.9%; p = 0.02) was greater in the IVL group, while flow-limiting dissections occurred more frequently in the PTA group (1.4% vs. 6.8%; p = 0.03). Post-dilatation (5.2% vs. 17.0%; p = 0.001) and stent placement (4.6% vs. 18.3%; p < 0.001) were also greater in the PTA group. The rates of major adverse events (IVL: 0% vs. PTA: 1.3%; p = 0.16) and clinically driven target lesion revascularization (IVL: 0.7% vs. PTA: 0.7%; p = 1.0) at 30 days were comparable between groups. IVL is an effective vessel preparation strategy that facilitates definitive endovascular treatment in calcified femoropopliteal arteries in patients with peripheral artery disease. (Shockwave Medical Peripheral Lithoplasty System Study for PAD [Disrupt PAD III]; NCT02923193).

1 May 2023 in JACC
Verified
Journal Article
Closed access
SKSusheel K. Kodali
Susheel K. Kodali
RHRebecca T Hahn
Rebecca T Hahn
CDCharles J. Davidson
Charles J. Davidson
ANAkhil Narang
Akhil Narang
AGAdam Greenbaum
Adam Greenbaum
MEMackram F. Eleid
Mackram F. Eleid

14 September 2022 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
WGWilliam A. Gray
William A. Gray
SASandra V. Abramson
Sandra V. Abramson
SLScott Lim
Scott Lim
DFDale Fowler
Dale Fowler
RSRobert L. Smith
Robert L. Smith
ACAnnie Cao
Annie Cao

1 October 2019 in Circulation
Verified
Journal Article
Open access
PDF file
WGWilliam A. Gray
William A. Gray
MJMichael R. Jaff
Michael R. Jaff
SPSahil A. Parikh
Sahil A. Parikh
GAGary M. Ansel
Gary M. Ansel
MBMarianne Brodmann
Marianne Brodmann
SLSean P. Lyden
Sean P. Lyden
Background: A recent summary-level meta-analysis comprising randomized, controlled trials (RCTs) of femoropopliteal paclitaxel-coated balloon and stent intervention identified excess late mortality in the paclitaxel-treated patients. Methods: We evaluated the safety of the Stellarex drug-coated balloon (DCB) for femoropopliteal artery disease with an independently performed meta-analysis of patient-level data from all patients in the Stellarex femoropopliteal clinical program. To compare mortality after DCB or uncoated percutaneous transluminal angioplasty (PTA), we aggregated data from 2 RCTs comprising 419 patients treated with DCB and 170 patients treated with PTA. In an additional analysis, data were aggregated from 6 poolable Stellarex DCB studies (2 RCTs, 3 single-arm studies, and 1 registry). All serious adverse events including deaths were adjudicated by a blinded, third-party, independent Clinical Events Committee. Kaplan–Meier estimates in the RCTs were compared with restricted mean survival time. Predictors of death were assessed with hazard ratios (HRs) and Cox proportional hazards modeling. Results: Baseline characteristics were similar in the patients treated with DCB and PTA in the pooled RCT analysis, with the exception that the DCB cohort was younger (67.4±9.7 versus 69.4±9.4 years, P =0.02), smoked more frequently (86.6% versus 78.8%, P =0.02), and were less often treated for recurrent lesions (8.8% versus 14.7%, P =0.04). In the RCTs, patients treated with DCB had all-cause mortality rates that were not different from those of patients treated with PTA (Kaplan–Meier estimates 1.8±0.7% versus 1.3±0.9%, 6.5±1.2% versus 5.9±1.9%, and 9.3±1.5% versus 9.9±2.4% at 1, 2, and 3 years, respectively, P =0.86). All-cause mortality rates were similar in a 1906-patient pooled nonrandomized DCB data set (Kaplan–Meier estimates of 2.1%, 4.9%, and 7.0% at 1, 2, and 3 years, respectively). Clinical Events Committee–adjudicated causes of death were balanced between the DCB and PTA cohorts. Multivariable Cox modeling identified age (HR, 1.06; 95% CI, 1.04–1.08; P <0.001), diabetes mellitus (HR, 1.42; 95% CI, 1.01–2.00; P =0.04), congestive heart failure (HR, 1.88; 95% CI, 1.12–3.16; P =0.02), and renal insufficiency (HR, 2.00; 95% CI, 1.33–3.01; P <0.001) as predictors of mortality. Paclitaxel exposure was unrelated to mortality (HR, 1.04; 95% CI, 0.98–1.10; P =0.23). Conclusions: The mortality rates for patients treated with the DCB and uncoated PTA were indistinguishable over 3-year follow-up. Additional patient-level, adequately powered meta-analyses with larger RCT data sets will be needed to confirm the generalizability of these findings. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifiers: NCT02110524, NCT01858363, NCT01858428, NCT03421561, NCT01912937, NCT01927068, and NCT02769273.

1 July 2018 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
WGWilliam A. Gray
William A. Gray
LGLawrence A. Garcia
Lawrence A. Garcia
AAAli Amin
Ali Amin
NSNicolas W. Shammas
Nicolas W. Shammas